Gray matter atrophy rate as a marker of disease progression in AD

Show simple item record

dc.contributor.author Anderson, Valerie en
dc.contributor.author Schott, JM en
dc.contributor.author Bartlett, JW en
dc.contributor.author Leung, KK en
dc.contributor.author Miller, DH en
dc.contributor.author Fox, NC en
dc.date.accessioned 2012-02-23T01:08:42Z en
dc.date.issued 2010-12-14 en
dc.identifier.citation Neurobiol Aging 14 Dec 2010 en
dc.identifier.uri http://hdl.handle.net/2292/11751 en
dc.description.abstract Global gray matter (GM) atrophy rates were quantified from magnetic resonance imaging (MRI) over 6- and 12-month intervals in 37 patients with Alzheimer's disease (AD) and 19 controls using: (1) nonlinear registration and integration of Jacobian values, and (2) segmentation and subtraction of serial GM volumes. Sample sizes required to power treatment trials using global GM atrophy rate as an outcome measure were estimated and compared between the 2 techniques, and to global brain atrophy measures quantified using the boundary shift integral (brain boundary shift integral; BBSI) and structural image evaluation, using normalization, of atrophy (SIENA). Increased GM atrophy rates (approximately 2% per year) were observed in patients compared with controls. Although mean atrophy rates provided by Jacobian integration were smaller than those from segmentation and subtraction of GM volumes, measurement variance was reduced. The number of patients required per treatment arm to detect a 20% reduction in GM atrophy rate over a 12-month follow-up (90% power) was 202 (95% confidence interval [CI], 118-423) using Jacobian integration and 2047 (95% CI 271 to > 10 000) using segmentation and subtraction. Comparable sample sizes for whole brain atrophy were 240 (95% CI, 142-469) using the BBSI and 196 (95% CI, 110-425) using SIENA. Jacobian integration could be useful for measuring GM atrophy rate in Alzheimer's disease as a marker of disease progression and treatment efficacy. en
dc.language ENG en
dc.publisher Elsevier Inc. en
dc.relation.ispartofseries Neurobiology of Aging en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0197-4580/ en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.title Gray matter atrophy rate as a marker of disease progression in AD en
dc.type Journal Article en
dc.identifier.doi 10.1016/j.neurobiolaging.2010.11.001 en
dc.rights.holder Copyright: Elsevier Inc. en
dc.identifier.pmid 21163551 en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Article en
pubs.elements-id 202942 en
dc.identifier.eissn 1558-1497 en
dc.identifier.pii S0197-4580(10)00475-6 en
pubs.record-created-at-source-date 2012-01-25 en
pubs.dimensions-id 21163551 en


Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics